Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease

Pediatrics

Volumn 135, Issue 3, 2015, Pages 495-503

  Yildirim, Inci ^a,b   Shea, Kimberly M ^a,b   Little, Brent A ^a   Silverio, Amy L ^a   Pelton, Stephen I ^a,b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; VACCINE;

AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASTHMA; BILE DUCT ATRESIA; CHILD; CHRONIC KIDNEY FAILURE; CHRONIC RESPIRATORY TRACT DISEASE; COCHLEA PROSTHESIS; COMORBIDITY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; NEPHROTIC SYNDROME; NEUROMUSCULAR DISEASE; PNEUMOCOCCAL INFECTION; PREMATURITY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SEIZURE; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION; BACTERIAL CAPSULE; FOLLOW UP; HEALTH SURVEY; IMMUNOLOGY; INFANT; PNEUMOCOCCAL INFECTIONS; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; MALE; MASSACHUSETTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84924308427     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2426     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep. 2010; 59(9):253-257
2. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201(1):32-41
3. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(6):468-472
4. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016-1027
5. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398-3412
6. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819
7. Talbot TR, Poehling KA, Hartert TV, et al. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J. 2004;23(8):726-731
8. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics. 2010; 126(1). Available at: www.pediatrics.org/cgi/content/full/126/1/e9
9. Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59(5):615-623
10. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495-1502
11. Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MPE, Miller E. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis. 2014;58(4):517-525
12. Yildirim I, Stevenson A, Hsu KK, Pelton SI. Evolving picture of invasive pneumococcal disease in Massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J. 2012;31(10):1016-1021
13. Centers for Disease Control and Prevention (CDC). National Immunization Survey. Available at: www.cdc.gov/nchs/nis.htm. Accessed April 2, 2014
14. American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012: 571-582
15. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(25):521-524
16. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9-16
17. Hjuler T, Wohlfahrt J, Staum Kaltoft M, Koch A, Biggar RJ, Melbye M. Risks of invasive pneumococcal disease in children with underlying chronic diseases. Pediatrics. 2008;122(1). Available at: www.pediatrics.org/cgi/content/full/122/1/e26
18. Carvalho MG, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol. 2007;45(8):2460-2466
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 15th Informational Supplement Approved Standard M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
20. US Census Bureau. www.census.gov. Accessed July 11, 2014
21. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: www.seer.cancer. gov. Accessed May 27, 2014
22. Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med. 2010;38(suppl 4):S512-S521
23. Payne AB, Link-Gelles R, Azonobi I, et al; Active Bacterial Core Surveillance Team. Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009. Pediatr Infect Dis J. 2013;32(12): 1308-1312
24. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447-3452
25. Yildirim I, Hanage WP, Lipsitch M, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 2010; 29(2):283-288
26. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis. 2003;187(9):1424-1432
27. Hsu KK, Shea KM, Stevenson AE, Pelton SI; Members of the Massachusetts Department of Public Health. Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J. 2011; 30(3):251-253
28. Pebody RG, Hippisley-Cox J, Harcourt S, Pringle M, Painter M, Smith G. Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999-2005. Epidemiol Infect. 2008;136(3): 360-369